AIIMS Launches Free Drug Monitoring Tests for Epilepsy Patients

AIIMS Introduces Free Testing for Epilepsy Medications

New Delhi, Jan 7: The All India Institute of Medical Sciences (AIIMS) has announced the launch of a complimentary therapeutic drug monitoring test specifically for individuals suffering from epilepsy.

Epilepsy is a long-term neurological condition characterized by recurrent seizures, which are caused by sudden, abnormal electrical discharges in the brain. These seizures can manifest as muscle spasms, confusion, loss of consciousness, or various psychological changes.

According to AIIMS, the new drug monitoring test will assess the levels of certain medications in a patient's bloodstream, ensuring that the prescribed dosages are both safe and effective.

“Patients with epilepsy often require multiple medications, and AIIMS has opted to offer free testing for monitoring drugs such as phenobarbital, carbamazepine, valproic acid, and phenytoin,” the institute stated.

“These therapeutic drug monitoring tests are essential for evaluating the effectiveness of the medications and determining the correct dosage. Additionally, they help identify any potential drug toxicity,” it further explained.

With this new initiative, patients will no longer need to seek testing services externally or incur any costs.

Previously, patients faced expenses ranging from Rs 390 to Rs 1,880 for therapeutic drug monitoring tests at outside facilities.

In a circular dated January 1, signed by Prof. Nirupam Madaan, Medical Superintendent, AIIMS instructed all departments and centers, including the National Cancer Institute (NCI), to forward patient samples to the designated laboratory for testing.

Both inpatients and outpatients are eligible for this testing service, as confirmed by the institute.

The service will be accessible to AIIMS Delhi outpatient department (OPD) patients at Collection Center Room Number 3 from 8:30 AM to 1:00 PM, and also at the National Cancer Institute located at AIIMS Jhajjar.